ACH-126443 Achillion/Yale University

Current Opinion in Investigational Drugs

Volumn 3, Issue 11, 2002, Pages 1580-1584

  Patel, Jignesh ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIVIRUS AGENT; ELVUCITABINE; ENTECAVIR; FAMCICLOVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS DNA;

CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; EXPERIMENTAL MODEL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANIMALS; CLINICAL TRIALS; HEPATITIS B; HIV INFECTIONS; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; TECHNOLOGY, PHARMACEUTICAL; ZALCITABINE;

EID: 0036881724     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. 207328 Design and synthesis of of 2′,3′-dideoxy-2′,3′-didehydro-β-L-cytidine (β-L-d4C) and 2′,3′-didehydro-β-L-5-fluorocytidine (β-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro. Lin TS, Luo MZ, Liu MC, Zhu YL, Gullen E, Dutschman GE, Cheng YC J Med Chem 1996 39 9 1757-1759
2. 213319 Vion pharmaceuticals receives notification of important patent allowance. Vion Pharmaceuticals Inc Press Release 1996 July 08
3. 247964 Vion pharmaceuticals awarded key patent for new HIV agent. Vion Pharmaceuticals Inc Press Release 1997 May 28
4. 274010 Bis-acyl-2-thiethyl (SATE)-bearing monophosphate prodrug of β-L-FD4C as a potent anti-HBV agent. Li X, Carmichael E, Feng M, King I, Doyle TW, Chen SH Bioorg Med Chem Lett 1998 8 1 57-62 A description of the synthesis of the monophosphate prodrug of β-L-Fd4C to improve its efficacy.
5. 283894 Interaction of β-L-2′,3′-dideoxy-2′,3′-didehydro-5-fluorocytidine 5′-triphosphate with HIV reverse transcriptase and human DNA polymerases: Implication for HIV drug design. Kukhanova M, Li X, Chen SH, King I, Doyle T, Prasoff W, Cheng YC Int Conf Antiviral Res 1998 11 April 5-10 Abs 1
6. 283996 Antiviral activity of a novel L-nucleoside analog, β-L-FD4C, in the duck HBV infection model. Le Guerhier F, Pichoud C, Chevallier M, Liu SH, Chen XY, Zoulim F Int Conf Antiviral Res 1998 11 April 5-10 Abs 21
7. 291568 Synthesis and biological evaluation of a series of 2′-fluorinated-2′,3′-dideoxy-2′,3′-didehydro-(L)-n ucleosides. Chen SH, Wang Q, Mao J, King I, Dutschman G, Gullen E, Cheng YC, Doyle T Bioorg Med Chem Lett 1998 8 13 1589-1594
8. 291968 Interaction of β-L-2′,3′-dideoxy-2′,3′-didehydro-5-fluoro-CTP with human immunodeficiency virus-1 reverse transcriptase and human DNA polymerases: Implications for human immunodeficiency virus drug design. Kukhanova M, Li X, Chen SH, King I, Doyle T, Prusoff W, Cheng YC Mol Pharmacol 1998 53 5 801-807 This paper describes a novel synthetic technique for β-L-Fd4C and also describes its molecular interaction with HIV reverse transcriptase.
9. 300131 Vion receives patent notifications. Vion Pharmaceuticals Inc Press Release 1998 October 01
10. 308486 Synthesis and comparative evaluation of two antiviral agents: β-L-FD4C and β-D-FD4C. Chen S, Lin S, King I, Spinka T, Dutschman GE, Gullen EA, Cheng Y, Doyle TW Bioorg Med Chem Lett 1998 8 22 3245-3250
11. 329793 Sensitivity of L-(-)2′,3′-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. Fu L, Liu SH, Cheng YC Biochem Pharmacol 1999 57 12 1351-1359 This paper reports the employment of HBV transient transfection system to study the mechanism of β-L-Fd4C, along with other nucleoside analogs, against lamivudine-resistant mutants.
12. 349263 Perspectives for the treatment of hepatitis B virus infections. De Clercq E Int J Antimicrob Agents 12 2 81-95
13. 355056 Achillion pharmaceuticals licenses Vion's antiviral agent for the treatment of hepatitis B (HBV) and human immunodeficiency virus-I (HIV). Vion Pharmaceuticals Inc Press Release 2000 February 08
14. 396322 Clinical potential of emerging new agents in hepatitis B. Farrell GC Drugs 2000 60 4 701-710
15. 401844 Characterization of the antiviral effect of 2′,3′-dideoxy-2′, 3′-didehydro-β-L-5-fluorocytidine in the duck hepatitis B virus infection model. Le Guerhier F, Pichoud C, Guerret S, Chevallier M, Jamard C, Hantz O, Li XY, Chen SH, King I, Trepo C, Cheng YC, Zoulim F Antimicrob Agents Chemother 2000 44 1 111-122 This paper reports that β-L-Fd4C suppresses duck-HBV reverse transcription and subsequently inhibits the initiation of infection and viral antigen expression in hepatocytes.
16. 401847 Anti-hepatitis B virus activity and metabolism of 2′,3′-dideoxy-2′,3′-didehydro-β-L(-)-5-fluoroxytidi ne. Zhu YL, Dutschman DE, Liu SH, Bridges EG, Cheng YC Antimicrob Agents Chemother 1998 42 7 1805-1810
17. 401848 Metabolism of 2′,3′-dideoxy-2′,3′-didehydro-β-L(-)-5-fluorocytidi ne and its activity in combination with clinically approved anti-human immunodeficiency virus β-D(+) nucleoside analogs in vitro. Dutschman GE, Bridges EG, Liu SH, Gullen E, Guo X, Kukhanova M, Cheng YC Antimicrob Agents Chemother 1998 42 7 1799-1804
18. 416722 Achillion pharmaceuticals starts phase Ib/II study in hepatitis B patients. Achillion Pharmaceuticals Inc Press Release 2001 July 24
19. 421492 Safety and pharmacokinetics of ACH-126,443, a potent anti-HIV and HBV nucleoside. Dunkle LM, Oshana S, Dickinson J, Cheng Y, Rice WG ICAAC 2001 41 Abs 508. A poster reporting the oral pharmacokinetics and safety profiles of β-L-Fd4C in healthy human volunteers.
20. 435422 HEP DART 2001 (Part I), frontiers in drug development for viral hepatitis, Kapalua, Maui, Hawaii. Dunkle LM IDDB Meeting Report 2001 December 16-20
21. 441756 Achillion pharmaceuticals initiates phase II study of lead product candidate in hepatitis B patients. Achillion Pharmaceuticals Inc Press Release 2002 February 28
22. 447898 Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: Selective phosphorylation of L-nucleoside analog diphosphates by 3-phosphoglycerate kinase. Krishnan P, Fu Q, Lam W, Liou JY, Dutschman G, Cheng YC J Biol Chem 2002 277 7 5453-5459
23. 447903 Antiviral activity of β-L-2′,3′-dideoxy-2′,3′-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus. Le Guerhier F, Pichoud C, Jamard C, Guerret S, Chevallier M, Peyrol S, Hantz O, King I, Trepo C, Cheng YC, Zoulim F Antimicrob Agents Chemother 2001 45 4 1065-1077
24. 447905 A novel action of human apurinic/apyrimidinic endonuclease: Excision of L-configuration deoxyribonucleoside analogs from the 3′ termini of DNA. Chou KM, Kukhanova M, Cheng YC J Biol Chem 2000 275 40 31009-31015. This paper provides data demonstrating that an exonuclease can preferentially excise L-configuration nucleoside analogs.
25. 452185 Achillion pharmaceuticals demonstrates potent anti-hepatitis B activity of lead product candidate in humans. Achillion Pharmaceuticals Inc Press Release 2002 May 22
26. 453099 Comparative evaluation of L-Fd4C and related nucleoside analogs as promising antiviral agents. Chen SH Curr Med Chem 9 9 899-912
27. 454316 Achillion; Product pipeline. Achillion Pharmaceuticals Inc Company World Wide Web Site 2002 June 11
28. 454485 Bio 2002 - International biotechnology convention and exhibition (Part V) - Overnight report, Toronto, Canada. IDDB Meeting Report 2002 June 09-12
29. 455232 Achillion pharmaceuticals Inc. Int Biotech Conv & Exhib 2002 Suppl June 9-12
30. 458304 Achillion pharmaceuticals launches HIV/AIDS clinical development program, a second indication for lead product candidate. Achillion Pharmaceuticals Inc Press Release 2002 July 17
31. 464241 Rapid, potent anti-HBV activity of ACH-126,443 in a phase I/II trial in chronic hepatitis B infection. Afdhal N, O'Brien C, Oshana S, Dunkle L ICAAC 2002 42 Abs V-690